MedTrace Logo

Phase 2a Study to Evaluate Safety and Explore Efficacy of J2H-1702 for NASH

NCT06297434 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2025-12-17

No results posted yet for this study

Summary

The study aims to evaluate the safety of J2H-1702 compared to the placebo and explore the efficacy of J2H-1702 at Week 12 timepoint after administration compared to baseline in patients with NASH.

Conditions

  • Non-alcoholic Steatohepatitis

Interventions

DRUG

J2H-1702

Orally, once daily before meals

DRUG

J2H-1702

Orally, once daily before meals

DRUG

J2H-1702

Orally, once daily before meals

DRUG

Placebo

Orally, once daily before meals

Sponsors & Collaborators

  • J2H Biotech

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-15
Primary Completion
2025-06-26
Completion
2025-11-05

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06297434 on ClinicalTrials.gov